We are your partner in early drug discovery for novel cancer treatment.

About us

We are your partner in early drug discovery for novel cancer treatment.

Founded in 2013, StemTek Therapeutics is an innovative biotech company based in Bilbao, Spain, specialized in cancer stem cell (CSC) research and drug discovery for novel anticancer therapies.

 

Stemtek Therapeutics believes in a CSC-centric approach to develop novel cancer treatments that put an end to relapse and metastasis. We partner with pharmaceutical and biotech companies to help you accelerate the early drug discovery process with enhanced biological relevance assays through enriched Cancer Stem Cell (CSC) 3D-based cell cultures.

Using state-of-the-art 3D tumor cell models, scientists at StemTek Therapeutics conduct rigorous analysis to push the boundaries in early stage drug screening. Stemtek Therapeutics has also developed a revolutionary and innovative Cell2Sphere™ product-kit that makes your 3D testing process reliable, easy to use and convenient.

With over thirty years combined experience in molecular and cellular oncology, StemTek Therapeutics goal is to help you accelerate treatments that put an end to cancer relapse. 

 
 

 

STEMTEK THERAPEUTICS WAS FOUNDED BY EXPERTS IN MOLECULAR AND CELLULAR BIOLOGY RESEARCH IN ONCOLOGY. 

Angel Garcia Martin and Olatz Leis Esnaola began their careers in academia achieving a deep knowledge of cancer stem cell biology. They built StemTek Therapeutics to translate this knowledge into the pharmaceutical industry and find a way to contribute to the fight against cancer by developing innovative anti-cancer stem cell therapeutics.  

 

Angel Garcia Martin, PhD MBA.

Angel is the CEO of StemTek Therapeutics, which he co-founded in 2013.  Angel is responsible for the overall direction and strategy of the company.  Trained as a scientist, he spent the early part of his career developing pioneering research in Molecular Oncology and stem cells at Centro de Biologia Molecular Severo Ochoa, National Cancer Institute (NIH) and Fundacion Inbiomed, where he served as Director of the Cancer Research Program and Director of the stem cell biobank. He holds a PhD in Biological Sciences from Universidad Autonoma de Madrid and a Masters in Business Administration. Angel is a member of StemTek Therapeutics’ Board of Directors.

 

Olatz Leis Esnaola, PhD.

Olatz is the COO of StemTek Therapeutics, which she co-founded in 2013, and is responsible for overseeing the company’s laboratory activities. Olatz received her PhD in Biological Sciences from the Universidad del Pais Vasco. Olatz trained as a postdoctoral scholar at Fundacion Inbiomed and the Università degli Studi di Milano-Bicocca. She has also participated in the setting up the Basque Brain biobank. Olatz is Chairman of StemTek Therapeutics’ Board of Directors.

 

Gabriel Inclan Blanco, MBA.

Gabriel is the CFO of StemTek Therapeutics, which he co-founded in 2013, and is responsible for overseeing the company’s finance and legal functions. Gabriel obtained his Bs degree in Economics and holds a Masters degree in Business Administration. Gabriel started his career as investment analyst at Lico Leasing, then served as Director of Finances at Proteomika SL. He started his own consulting firm in Bilbao, Mendoza e Inclan to support legal and financial governance of his customers. Gabriel is a member of StemTek Therapeutics’ Board of Directors.

 

Laureano Simon.

Laureano is an investor and member of the Board of Directors since 2016. He has founded, invested, and served as a director for over a dozen companies in the private biotech sector. Laureano was the founder and CEO of Progenika Biopharma, which he later sold to Grifols. Laureano has received the Eurowards Award for Entrepreneurs (2004), Ernst & Young Most Innovative Entrepreneur (2010), and the Ruban d´honneur in the European Business Awards, HSBC Bank (2011). He holds a PhD in Biochemistry and Molecular Biology from the Universidad Autonoma de Madrid, a MSc in Biotechnology from the University of Navarre, a MSc from the University of Wisconsin-Madison, and a BSc in Pharmacy from the University of Santiago de Compostela.

 

 
 

INVESTORS


StemTek Therepeutics is expanding and we are always looking for strategic partnerships to help us bring novel treatments to cancer patients. If you are interested in learning how your business can take advantage of our technology, or if you would like to learn more about how you can invest in our mission, please contact us today.

 

 

 
Back to top